MedTrace Logo

Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

NCT06536400 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 316

Last updated 2024-08-05

No results posted yet for this study

Summary

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360 when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.

Conditions

Interventions

DRUG

HSK42360

Oral administration, QD

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-25
Primary Completion
2026-08-30
Completion
2027-07-07

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06536400 on ClinicalTrials.gov